HK1107814A1 - Thiadiazoline derivatives for treating cancer - Google Patents

Thiadiazoline derivatives for treating cancer

Info

Publication number
HK1107814A1
HK1107814A1 HK08101484.3A HK08101484A HK1107814A1 HK 1107814 A1 HK1107814 A1 HK 1107814A1 HK 08101484 A HK08101484 A HK 08101484A HK 1107814 A1 HK1107814 A1 HK 1107814A1
Authority
HK
Hong Kong
Prior art keywords
substituted
unsubstituted
treating cancer
unsubstituted lower
hydrogen atom
Prior art date
Application number
HK08101484.3A
Other languages
English (en)
Inventor
Chikara Murakata
Kazuhiko Kato
Yoshihisa Ohta
Ryuichiro Nakai
Yoshinori Yamashita
Takeshi Takahashi
Tomohisa Nakano
Yoji Ino
Original Assignee
Kyowa Hakko Kirin Co Ltd
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd, Fujifilm Corp filed Critical Kyowa Hakko Kirin Co Ltd
Publication of HK1107814A1 publication Critical patent/HK1107814A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
HK08101484.3A 2001-12-11 2008-02-06 Thiadiazoline derivatives for treating cancer HK1107814A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001377456 2001-12-11
JP2002237399 2002-08-16

Publications (1)

Publication Number Publication Date
HK1107814A1 true HK1107814A1 (en) 2008-04-18

Family

ID=26624996

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08101484.3A HK1107814A1 (en) 2001-12-11 2008-02-06 Thiadiazoline derivatives for treating cancer

Country Status (16)

Country Link
US (4) US7425636B2 (xx)
EP (2) EP1847534B9 (xx)
JP (1) JP4272994B2 (xx)
KR (1) KR100915287B1 (xx)
CN (1) CN100484928C (xx)
AT (2) ATE480527T1 (xx)
AU (1) AU2002354465B2 (xx)
CA (1) CA2469801C (xx)
CY (2) CY1112899T1 (xx)
DE (1) DE60237637D1 (xx)
DK (2) DK1454903T3 (xx)
ES (1) ES2350642T3 (xx)
HK (1) HK1107814A1 (xx)
PT (2) PT1847534E (xx)
SI (2) SI1454903T1 (xx)
WO (1) WO2003051854A1 (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1847534E (pt) * 2001-12-11 2011-08-01 Kyowa Hakko Kirin Co Ltd Derivado de tiadiozolina para o tratamento do cancro
EP1616866B1 (en) * 2003-04-18 2011-12-14 Kyowa Hakko Kirin Co., Ltd. M-stage kinesin inhibitor
WO2004111024A1 (ja) * 2003-06-10 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. チアジアゾリン誘導体
JPWO2004111023A1 (ja) * 2003-06-10 2006-07-27 協和醗酵工業株式会社 チアジアゾリン−１−オキシド誘導体
JPWO2005035512A1 (ja) * 2003-10-10 2006-12-21 協和醗酵工業株式会社 チアジアゾリン誘導体
WO2005061707A1 (ja) * 2003-12-24 2005-07-07 Kyowa Hakko Kogyo Co., Ltd. 癌細胞のEg5阻害剤に対する感受性を判定する方法
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
CN101193878A (zh) * 2005-03-22 2008-06-04 协和发酵工业株式会社 实体肿瘤治疗剂
US20080262049A1 (en) * 2005-03-22 2008-10-23 Kyowa Hakko Kogyo Co., Ltd. Therapeutic Agent for Hematopoietic Tumor
UA95907C2 (xx) * 2005-05-02 2011-09-26 Эррей Биофарма Инк. Інгібітори мітотичних кінезинів та їх використання$ингибиторы митотических кинезинов и их использование
EP1908755A4 (en) * 2005-06-24 2009-06-24 Kyowa Hakko Kirin Co Ltd THERAPEUTIC AGENT AGAINST RESTENOSIS
DE102005055354A1 (de) * 2005-11-21 2007-10-31 Merck Patent Gmbh Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine
DE102006002065B4 (de) * 2006-01-16 2007-11-29 Infineon Technologies Austria Ag Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand
WO2008042928A2 (en) * 2006-10-03 2008-04-10 Array Biopharma, Inc. Oxadiazole and thiadiazole derivatives as mitotic kinesin inhibitors and methods of use thereof
CA2694277C (en) 2007-07-12 2013-04-09 Eli Lilly And Company Stable formulations of thiadiazole derivatiive
TW200934785A (en) * 2007-10-19 2009-08-16 Schering Corp Compounds for inhibiting KSP kinesin activity

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE244989C (xx)
US4246225A (en) * 1978-05-25 1981-01-20 Owens-Illinois, Inc. Method for forming tubular plastic articles
US4338449A (en) * 1981-06-15 1982-07-06 Eli Lilly And Company Herbicidal thiadiazolines
US4346225A (en) 1981-06-15 1982-08-24 Eli Lilly And Company Herbicidal 2-methylamino thiadiazolines
US4699913A (en) 1985-06-28 1987-10-13 Ciba-Geigy Corporation Substituted 4,5-dihydro-1,3,4-thiadiazoles useful as insecticides
ATE72431T1 (de) 1985-08-31 1992-02-15 Fisons Plc 5-gliedrige heterocyclische angiotensinumwandlungsenzym-inhibitoren.
DD243930A1 (de) 1985-12-04 1987-03-18 Akad Wissenschaften Ddr Verfahren zur herstellung von neuen 5,5-disubstituierten 4-carbamoyl-4,5-dihydro-1,3,4-thiadiazol-2-yl-harnstoffen
WO1993022311A1 (en) 1992-04-27 1993-11-11 E.I. Du Pont De Nemours And Company Fungicidal 1,3,4-oxadiazines and 1,3,4-thiadiazines
ATE157871T1 (de) * 1994-05-19 1997-09-15 Mitsubishi Chem Corp Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind
JP2798005B2 (ja) 1994-05-19 1998-09-17 三菱化学株式会社 平滑筋細胞増殖に起因する疾患の治療・予防剤
US5814647A (en) 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms
US6235762B1 (en) 1998-11-23 2001-05-22 American Cyanamid Company 2-aryl-Δ2-1,3,4-(oxa and thia)diazoline insecticidal and acaricidal agents
JP2000159756A (ja) 1998-11-23 2000-06-13 American Cyanamid Co ２―アリ―ル―δ２―１，３，４―（オキサおよびチア）ジアゾリン殺虫および殺ダニ剤
JP2000204077A (ja) 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
CN1149204C (zh) 1999-01-13 2004-05-12 沃尼尔·朗伯公司 1-杂环取代的二芳基胺
JP2000229959A (ja) * 1999-02-04 2000-08-22 Sumitomo Pharmaceut Co Ltd Ｓｔａｔ６活性化阻害剤
US6617115B1 (en) 1999-10-27 2003-09-09 Cytokinetics, Inc. Methods of screening for modulators of cell proliferation
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
MXPA02004162A (es) 1999-10-27 2003-08-20 Cytokinetics Inc Metodo y composiciones que utilizan quinazolinonas.
WO2001056994A1 (en) * 2000-02-04 2001-08-09 Biogen, Inc. Integrin antagonists
US6310716B1 (en) 2000-08-18 2001-10-30 Corning Incorporated Amplifier system with a discrete Raman fiber amplifier module
US6992082B2 (en) 2001-01-19 2006-01-31 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
US20040132830A1 (en) 2001-01-19 2004-07-08 Finer Jeffrey T Triphenylmethane kinesin inhibitors
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20020165240A1 (en) 2001-03-29 2002-11-07 Kimball Spencer David Method of treating proliferative diseases using Eg5 inhibitors
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6809102B2 (en) 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
AU2002363429B2 (en) * 2001-11-07 2008-05-08 Merck & Co., Inc. Mitotic kinesin inhibitors
PT1847534E (pt) 2001-12-11 2011-08-01 Kyowa Hakko Kirin Co Ltd Derivado de tiadiozolina para o tratamento do cancro
US6561831B1 (en) 2001-12-27 2003-05-13 Hon Hai Precision Ind. Co., Ltd. Housing of socket connector and conductive terminal thereof
AU2003249597B2 (en) 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
JP2006506401A (ja) * 2002-05-23 2006-02-23 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害薬
EP1616866B1 (en) 2003-04-18 2011-12-14 Kyowa Hakko Kirin Co., Ltd. M-stage kinesin inhibitor
JPWO2004111023A1 (ja) 2003-06-10 2006-07-27 協和醗酵工業株式会社 チアジアゾリン−１−オキシド誘導体
WO2004111024A1 (ja) 2003-06-10 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. チアジアゾリン誘導体
JPWO2005035512A1 (ja) * 2003-10-10 2006-12-21 協和醗酵工業株式会社 チアジアゾリン誘導体
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
CN101193878A (zh) 2005-03-22 2008-06-04 协和发酵工业株式会社 实体肿瘤治疗剂
US20080262049A1 (en) 2005-03-22 2008-10-23 Kyowa Hakko Kogyo Co., Ltd. Therapeutic Agent for Hematopoietic Tumor
EP1908755A4 (en) 2005-06-24 2009-06-24 Kyowa Hakko Kirin Co Ltd THERAPEUTIC AGENT AGAINST RESTENOSIS

Also Published As

Publication number Publication date
AU2002354465B2 (en) 2008-11-20
DK1454903T3 (da) 2010-11-22
EP1847534B1 (en) 2011-06-22
DE60237637D1 (de) 2010-10-21
EP1454903A1 (en) 2004-09-08
SI1454903T1 (sl) 2010-12-31
PT1454903E (pt) 2010-11-09
KR20040072649A (ko) 2004-08-18
DK1847534T3 (da) 2011-08-29
US7902234B2 (en) 2011-03-08
CN100484928C (zh) 2009-05-06
US20060074113A1 (en) 2006-04-06
JP4272994B2 (ja) 2009-06-03
AU2002354465A1 (en) 2003-06-30
ATE480527T1 (de) 2010-09-15
EP1847534A3 (en) 2008-09-24
EP1454903A4 (en) 2005-12-21
EP1454903B1 (en) 2010-09-08
CY1111816T1 (el) 2015-10-07
EP1847534B9 (en) 2012-03-21
CN1617864A (zh) 2005-05-18
KR100915287B1 (ko) 2009-09-03
EP1847534A2 (en) 2007-10-24
ATE513821T1 (de) 2011-07-15
US20100240716A1 (en) 2010-09-23
SI1847534T1 (sl) 2011-10-28
CA2469801A1 (en) 2003-06-26
ES2350642T3 (es) 2011-01-25
PT1847534E (pt) 2011-08-01
US7425636B2 (en) 2008-09-16
WO2003051854A1 (en) 2003-06-26
US20070213380A1 (en) 2007-09-13
US7759371B2 (en) 2010-07-20
CA2469801C (en) 2011-06-21
US20080207706A1 (en) 2008-08-28
EP1454903B9 (en) 2011-10-05
CY1112899T1 (el) 2016-04-13
JPWO2003051854A1 (ja) 2005-04-28

Similar Documents

Publication Publication Date Title
HK1107814A1 (en) Thiadiazoline derivatives for treating cancer
HK1158637A1 (en) Mitotic kinesin inhibitor m
PT705833E (pt) Derivado de dc-89
NO20012617D0 (no) Kinolin- og kinzolinderivater
EP1902716A4 (en) PROPHYLACTIC AND / OR THERAPEUTIC AGENT FOR MOTOR TROUBLESHOOTING
TW200726470A (en) 6,7-unsaturated-7-carbamoylmorphinan derivatives
TR200403436T2 (tr) Kristalin 1-metilkarbapenem türevleri.
NO20025035D0 (no) Oksadiazolderivater som har anticancer-effekter
EP1671957A4 (en) THIADIAZOLINDERIVATE
DK0882728T3 (da) 1-methylcarbapenemderivater
EP1152004A4 (en) PHOSPHONIC ACID DERIVATIVES HAVING CARBOXYPEPTIDASE B INHIBITOR ACTIVITY
EP1156037A4 (en) PROMOTERS OF CHONDROGENESIS AND INDOLIN-2-ONE DERIVATIVES
ATE320417T1 (de) Naphthimidobenzamid-derivate
DK1433480T3 (da) Lægemiddel indeholdende pyrimidin-derivat
EP1234576A4 (en) MEDICINE AGAINST EATING DISORDERS
MX9704976A (es) Derivados de 1,2,3-benzotiadiazol.
EP1251129A4 (en) PYRIMIDINE DERIVATIVES WITH ANTI-TUMOR EFFECT

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20141211